# Draft 1: Prostate cancer transcriptomic data for biotrain


# Introduction to Prostate Cancer and TCGA Transcriptomic Data

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death among men in many parts of the world. It is a biologically heterogeneous disease, ranging from indolent tumors that may not require treatment to aggressive forms with a high risk of metastasis and mortality. Understanding the molecular landscape of prostate cancer is critical for improving diagnosis, risk stratification, and treatment strategies.

Advancements in high-throughput technologies have enabled comprehensive profiling of the transcriptome in cancer tissues. Transcriptomic data provide insights into gene expression changes that drive tumor progression, response to therapy, and clinical outcomes. These molecular features can be integrated with clinical variables to develop predictive models and guide personalized treatment.

## The Cancer Genome Atlas (TCGA)

The Cancer Genome Atlas (TCGA) is a landmark initiative launched by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to systematically characterize the genomic and molecular alterations across more than 30 types of cancer. For prostate cancer, the TCGA-PRAD dataset includes extensive transcriptomic data (RNA-Seq) alongside detailed clinical annotations from patients with primary prostate adenocarcinoma. This resource enables integrative analyses to uncover clinically relevant biomarkers and molecular subtypes.

## Clinical Variables

The dataset includes several clinically relevant variables that are critical for understanding disease presentation and outcomes:

- **Age**: Age at diagnosis is a key demographic factor associated with disease incidence and progression.
- **Initial Weight**: Body weight at diagnosis may correlate with metabolic status and prognosis.
- **Histological Type**: Describes the microscopic characteristics of tumor cells; prostate adenocarcinoma is the most common histological subtype.
- **ISUP Grade Group**: A modern classification of histological characteristics, ranging from Grade Group 1 (least aggressive) to Grade Group 5 (most aggressive), used for prognostication.
- **Laterality**: Indicates whether the tumor affects one (unilateral) or both (bilateral) lobes of the prostate.
- **PSA (Prostate-Specific Antigen)**: A widely used biomarker for PCa diagnosis and monitoring; elevated levels may indicate tumor burden.
- **Targeted Molecular Therapy**: Refers to the administration of drugs that specifically target molecular pathways altered in cancer cells.
- **Radiation Therapy**: Indicates whether the patient received radiation as part of initial or adjuvant treatment.
- **Initial Pathologic Diagnosis Method**: Refers to the diagnostic technique used (e.g., needle biopsy, TURP, prostatectomy) for confirming prostate cancer.

Together, these variables and transcriptomic features allow the development of machine learning models to predict outcomes and inform clinical decision-making in prostate cancer management.
